Serum levels of transforming growth factor β1 in patients with breast cancer

S. M. Sheen-Chen, H. S. Chen, C. W. Sheen, H. L. Eng, W. J. Chen

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Hypothesis: Transforming growth factor β1 (TGF-β1 may be related to breast cancer progression. Design: Prospective study. Setting: University hospital. Patients: Sixty consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated. The control group consisted of 14 patients with benign breast tumors (7 with fibrocystic disease and 7 with fibroadenoma). Intervention: Venous blood samples were collected before the surgery. Sera were obtained by centrifugation and stored at -70°C until assayed. Serum concentrations of TGF-β1 were measured by quantitative sandwich enzyme immunoassay. Data on primary tumor stage, age, estrogen receptor status, lymph node status, distant metastases, and TNM staging (according to the Union Internationale Centre le Cancer) were reviewed and recorded. Main Outcome Measures: Measurements of preoperative serum TGF-β1 levels in patients with breast cancer. Results: The mean±SD value of serum TGF-β1 in patients with invasive breast cancer was 498.7 ± 249.7 pg/mL and in the control group was 495.2 ± 225.5 pg/mL (P = .96). However, there were significantly higher serum levels of TGF-β1 in patients with more advanced lymph node status (P =.04), more advanced TNM stage (P =.005), and poorer histological grade (P = .02). In multivariate analysis, TNM staging (P = .02) was demonstrated to be the independent factor related to significantly higher serum levels of TGF-β1. Conclusions: Patients with more advanced TNM stages were shown to have higher serum TGF-β1 levels. Thus, serum TGF-β1 levels may reflect the severity of invasive breast cancer.

Original languageEnglish
Pages (from-to)937-940
Number of pages4
JournalArchives of Surgery
Volume136
Issue number8
DOIs
Publication statusPublished - Jan 1 2001

Fingerprint

Transforming Growth Factors
Breast Neoplasms
Serum
Neoplasm Staging
Lymph Nodes
Fibroadenoma
Control Groups
Immunoenzyme Techniques
Centrifugation
Estrogen Receptors
Neoplasms
Multivariate Analysis
Outcome Assessment (Health Care)
Prospective Studies
Neoplasm Metastasis

ASJC Scopus subject areas

  • Surgery

Cite this

Serum levels of transforming growth factor β1 in patients with breast cancer. / Sheen-Chen, S. M.; Chen, H. S.; Sheen, C. W.; Eng, H. L.; Chen, W. J.

In: Archives of Surgery, Vol. 136, No. 8, 01.01.2001, p. 937-940.

Research output: Contribution to journalArticle

Sheen-Chen, S. M. ; Chen, H. S. ; Sheen, C. W. ; Eng, H. L. ; Chen, W. J. / Serum levels of transforming growth factor β1 in patients with breast cancer. In: Archives of Surgery. 2001 ; Vol. 136, No. 8. pp. 937-940.
@article{7d68f420e93a4327ae79ee1fab2df654,
title = "Serum levels of transforming growth factor β1 in patients with breast cancer",
abstract = "Hypothesis: Transforming growth factor β1 (TGF-β1 may be related to breast cancer progression. Design: Prospective study. Setting: University hospital. Patients: Sixty consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated. The control group consisted of 14 patients with benign breast tumors (7 with fibrocystic disease and 7 with fibroadenoma). Intervention: Venous blood samples were collected before the surgery. Sera were obtained by centrifugation and stored at -70°C until assayed. Serum concentrations of TGF-β1 were measured by quantitative sandwich enzyme immunoassay. Data on primary tumor stage, age, estrogen receptor status, lymph node status, distant metastases, and TNM staging (according to the Union Internationale Centre le Cancer) were reviewed and recorded. Main Outcome Measures: Measurements of preoperative serum TGF-β1 levels in patients with breast cancer. Results: The mean±SD value of serum TGF-β1 in patients with invasive breast cancer was 498.7 ± 249.7 pg/mL and in the control group was 495.2 ± 225.5 pg/mL (P = .96). However, there were significantly higher serum levels of TGF-β1 in patients with more advanced lymph node status (P =.04), more advanced TNM stage (P =.005), and poorer histological grade (P = .02). In multivariate analysis, TNM staging (P = .02) was demonstrated to be the independent factor related to significantly higher serum levels of TGF-β1. Conclusions: Patients with more advanced TNM stages were shown to have higher serum TGF-β1 levels. Thus, serum TGF-β1 levels may reflect the severity of invasive breast cancer.",
author = "Sheen-Chen, {S. M.} and Chen, {H. S.} and Sheen, {C. W.} and Eng, {H. L.} and Chen, {W. J.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1001/archsurg.136.8.937",
language = "English",
volume = "136",
pages = "937--940",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Serum levels of transforming growth factor β1 in patients with breast cancer

AU - Sheen-Chen, S. M.

AU - Chen, H. S.

AU - Sheen, C. W.

AU - Eng, H. L.

AU - Chen, W. J.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Hypothesis: Transforming growth factor β1 (TGF-β1 may be related to breast cancer progression. Design: Prospective study. Setting: University hospital. Patients: Sixty consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated. The control group consisted of 14 patients with benign breast tumors (7 with fibrocystic disease and 7 with fibroadenoma). Intervention: Venous blood samples were collected before the surgery. Sera were obtained by centrifugation and stored at -70°C until assayed. Serum concentrations of TGF-β1 were measured by quantitative sandwich enzyme immunoassay. Data on primary tumor stage, age, estrogen receptor status, lymph node status, distant metastases, and TNM staging (according to the Union Internationale Centre le Cancer) were reviewed and recorded. Main Outcome Measures: Measurements of preoperative serum TGF-β1 levels in patients with breast cancer. Results: The mean±SD value of serum TGF-β1 in patients with invasive breast cancer was 498.7 ± 249.7 pg/mL and in the control group was 495.2 ± 225.5 pg/mL (P = .96). However, there were significantly higher serum levels of TGF-β1 in patients with more advanced lymph node status (P =.04), more advanced TNM stage (P =.005), and poorer histological grade (P = .02). In multivariate analysis, TNM staging (P = .02) was demonstrated to be the independent factor related to significantly higher serum levels of TGF-β1. Conclusions: Patients with more advanced TNM stages were shown to have higher serum TGF-β1 levels. Thus, serum TGF-β1 levels may reflect the severity of invasive breast cancer.

AB - Hypothesis: Transforming growth factor β1 (TGF-β1 may be related to breast cancer progression. Design: Prospective study. Setting: University hospital. Patients: Sixty consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated. The control group consisted of 14 patients with benign breast tumors (7 with fibrocystic disease and 7 with fibroadenoma). Intervention: Venous blood samples were collected before the surgery. Sera were obtained by centrifugation and stored at -70°C until assayed. Serum concentrations of TGF-β1 were measured by quantitative sandwich enzyme immunoassay. Data on primary tumor stage, age, estrogen receptor status, lymph node status, distant metastases, and TNM staging (according to the Union Internationale Centre le Cancer) were reviewed and recorded. Main Outcome Measures: Measurements of preoperative serum TGF-β1 levels in patients with breast cancer. Results: The mean±SD value of serum TGF-β1 in patients with invasive breast cancer was 498.7 ± 249.7 pg/mL and in the control group was 495.2 ± 225.5 pg/mL (P = .96). However, there were significantly higher serum levels of TGF-β1 in patients with more advanced lymph node status (P =.04), more advanced TNM stage (P =.005), and poorer histological grade (P = .02). In multivariate analysis, TNM staging (P = .02) was demonstrated to be the independent factor related to significantly higher serum levels of TGF-β1. Conclusions: Patients with more advanced TNM stages were shown to have higher serum TGF-β1 levels. Thus, serum TGF-β1 levels may reflect the severity of invasive breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034911060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034911060&partnerID=8YFLogxK

U2 - 10.1001/archsurg.136.8.937

DO - 10.1001/archsurg.136.8.937

M3 - Article

C2 - 11485532

AN - SCOPUS:0034911060

VL - 136

SP - 937

EP - 940

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 8

ER -